Home > Search Results

Treats high blood pressure and angina (chest pain). This medicine is a calcium channel blocker.

UsesSide effectsLatest evidence reviewsResearch summaries for consumersBrand names

Results: 41 to 60 of 88

An updated meta-analysis of calcium-channel blockers in the prevention of restenosis after coronary angioplasty

This review found that treatment with calcium-channel blockers after percutaneous transluminal coronary angioplasty can be considered a safe and probably cost-effective strategy for reducing the need for revascularisations. Quality assessment of included studies was not reported, and its unclear whether appropriate steps were taken to avoid bias in the review process. The conclusions are not supported by the analysis presented.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2003

Racial differences in blood pressure response to calcium channel blocker monotherapy: a meta-analysis

The review concluded that blood pressure response to calcium channel blocker monotherapy was qualitatively similar in blacks and whites in USA. The authors' conclusions appeared to broadly reflect the evidence presented, but the restriction of using only trial data and limitations in the review processes made their reliability uncertain.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2009

The development of new-onset type 2 diabetes associated with choosing a calcium channel blocker compared to a diuretic or beta-blocker

This review concluded that calcium-channel blockers for the treatment of hypertension appear to reduce the risk of developing new-onset type two diabetes mellitus compared with treatment with β-blockers and/or diuretics. However, given the differences between the studies and several potential limitations of the review methodology, the reliability of the authors' conclusions is unclear.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2007

Are calcium antagonists beneficial in diabetic patients with hypertension?

This review, which assessed the effects of calcium antagonists in hypertensive patients with diabetes mellitus, was poorly conducted and reported. The authors concluded that calcium antagonists are safe and effective in reducing most types of cardiovascular morbidity and mortality in diabetic hypertensive patients. However, given the many limitations of the review, these conclusions must be treated with caution.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2004

Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158 998 patients

The review concluded that treatment with angiotensin-converting enzyme inhibitors resulted in a significant further reduction in all-cause mortality in patients with hypertension. The authors’ conclusions were based on the evidence and seem reliable but the unclear quality of the evidence base should be considered when interpreting the review.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2012

Drug Class Review: Beta Adrenergic Blockers: Final Report Update 4 [Internet]

Beta blockers inhibit the chronotropic, inotropic, and vasoconstrictor responses to the catecholamines, epinephrine, and norepinephrine. Beta blockers differ in their duration of effect (3 hours to 22 hours), the types of beta receptors they block (β1-selective or β1/β2-nonselective), whether they are simultaneously capable of exerting low level heart rate increases (intrinsic sympathomimetic activity [ISA]), and in whether they provide additional blood vessel dilation effects by also blocking alpha-1 receptors. All beta blockers are approved for the treatment of hypertension. Other US Food and Drug Administration-approved uses are specific to each beta blocker and include stable and unstable angina, atrial arrhythmias, bleeding esophageal varices, coronary artery disease, asymptomatic and symptomatic heart failure, migraine, and secondary prevention of post-myocardial infarction. The objective of this review was to evaluate the comparative effectiveness and harms of beta blockers in adult patients with hypertension, angina, coronary artery bypass graft, recent myocardial infarction, heart failure, atrial arrhythmia, migraine or bleeding esophageal varices.

Drug Class Reviews - Oregon Health & Science University.

Version: July 2009
Show search results within this document

Dietary Supplements in Adults Taking Cardiovascular Drugs [Internet]

A substantial proportion of patients with cardiovascular diseases use dietary supplements in anticipation of benefit. This also poses risks of adverse events from supplement-drug interactions and nonadherence associated with polypharmacy.

Comparative Effectiveness Reviews - Agency for Healthcare Research and Quality (US).

Version: April 2012
Show search results within this document

Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis

The authors concluded that ACEIs reduced all-cause mortality, cardiovascular mortality and major cardiovascular events in patients with diabetes mellitus whereas ARBs had no beneficial effects on these outcomes. These conclusions reflect the evidence presented and appear reliable.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2014

Results of a meta-analysis comparing the tolerability of lercanidipine and other dihydropyridine calcium channel blockers

This review concluded that lercanidipine was associated with a lower risk of peripheral oedema and treatment withdrawal due to peripheral edema when compared with first-generation dihydropyridine calcium channel blockers, but not when compared with second-generation drugs. A degree of caution might be required in interpreting the authors' conclusions given the limited quality of included studies.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2009

Meta-analysis of randomized and controlled treatment trials for achalasia

The authors concluded that based on limited evidence, laparoscopic myotomy was the preferred method for treating patients with achalasia. Evidence appeared to support the authors’ conclusions, but the authors acknowledged that evidence was limited and this should be taken into account when interpreting review findings.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2009

ACEI/ARB therapy for IgA nephropathy: a meta analysis of randomised controlled trials

The authors concluded that angiotensin converting-enzyme inhibitor/angiotensin II receptor blocker agents appeared to improve proteinuria and have a protecting effect on renal function. Given potential sources of bias that included methodological variability, inclusion of studies with small samples sizes and use concomitant medication by participants, the authors' conclusions should be treated with caution.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2009

Screening to prevent spontaneous preterm birth: systematic reviews of accuracy and effectiveness literature with economic modelling

A viable preterm birth is defined as any delivery of a pregnancy at less than 37 completed weeks (< 259 days) and more than 23 completed weeks of gestation. It is a heterogeneous condition where 30–40% of all cases of preterm births are the result of elective delivery for a maternal or a fetal complication. The remaining 60–70% of preterm births occur spontaneously, and these are the focus of this report. Preterm birth complicates about 3% of pregnancies before 34 weeks’ gestation and between 7 and 12% before 37 weeks’ gestation. The former particularly has serious effects on mother, child and society, making preterm birth an important issue to public health worldwide. If women can be identified to be at high risk in early pregnancy, they can be targeted for more intensive antenatal surveillance and prophylactic interventions. When women present with symptoms of threatened preterm labour, if the likelihood of having a spontaneous preterm birth can be determined, interventions can be deployed to prevent or delay birth and to improve subsequent neonatal mortality/morbidity.

NIHR Health Technology Assessment programme: Executive Summaries - NIHR Journals Library.

Version: 2009

Race and ethnicity in trials of antihypertensive therapy to prevent cardiovascular outcomes: a systematic review

The authors' conclusion appears to be that in cardiovascular disease prevention trials of antihypertensive therapies, treatment efficacy was similar for white and ethnic minorities for the primary outcomes. However, owing to the methodology used in the review, these results should be considered as exploratory rather than conclusive.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2007

Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate; a meta-analysis of randomized trials

The review concluded that incidence of peripheral oedema and patient withdrawal increased with duration of calcium channel blocker therapy up to six months. Rates were lower with both non-dihydropyridines and lipophilic dihydropyridines. Given lack of clarity on quality and potential for bias in the review process, the authors' conclusions should be considered tentative.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2011

Do calcium channel blockers increase the diagnosis of heart failure in patients with hypertension?

The review concluded that the results suggested patients with hypertension treated with calcium channel blockers had an increased incidence of heart failure, but that this effect should be researched further. Despite some potential limitations with the review process, and uncertain definitions of heart failure in the included trials (noted by the authors), the authors’ cautious conclusions reflect the evidence presented.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2010

Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring: a meta-analysis of randomized trials

The authors concluded that hydrochlorothiazide (12.5mg to 25mg daily dose) lowered blood pressure significantly less well than other drug classes used to treat hypertension (measured by 24-hour ambulatory blood pressure monitoring). The reliability of the authors' conclusion is uncertain given potential error and bias in the review process and reliance on only a few high-quality trials.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2011

Calcium antagonists reduce cardiovascular complications after cardiac surgery: a meta-analysis

This review assessed the efficacy of calcium antagonists for reducing mortality and complications following coronary artery bypass graft or valve surgery. The authors concluded that treatment reduced complications but not mortality. The review had some methodological and reporting limitations (participant characteristics were not reported), but the authors' conclusions were conservative and appear likely to be reliable

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2003

Medical therapy to facilitate urinary stone passage: a meta-analysis

This review assessed the efficacy of calcium-channel or alpha blockers to treat urinary stone disease. The authors concluded that medical therapy appeared to be an option for patients amenable to conservative management, potentially obviating surgery, but a high-quality randomised trial was necessary. The conclusion appears reliable with the reservation that medical therapy was not directly compared with surgery within the reviewed studies.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2006

Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and Bayesian random-effects meta-analyses of randomized trials

This generally well-conducted review concluded that available evidence suggested intensive blood pressure control (135mmHg or lower) reduced the risk of macrovascular events (death or stroke) in participants with type 2 diabetes mellitus/impaired fasting glucose or glucose intolerance, but increased the risk of serious adverse events. The authors' conclusions are likely to be reliable.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2011

Meta-analysis: effect of ACE-inhibitors on outcomes in patients with renal insufficiency

This review assessed the efficacy of angiotensin-converting enzyme (ACE) inhibitors in slowing the progression to end-stage renal failure in patients with renal disease. The authors concluded that ACE inhibitors are effective in slowing the progression of renal insufficiency regardless of baseline serum creatinine levels. Poor reporting of the review process makes it difficult to verify this conclusion.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2003

Systematic Reviews in PubMed

See all (161)...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...